Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 199-212

  Kuroki, Toshihide ^a   Nagao, Naoko ^a   Nakahara, Tatsuo ^a  

^a National Hospital Organization Hizen Psychiatric Center   (Japan)

Author keywords

5 HT1A receptor; 5 HT2A receptor; dopamine D2 receptor; second generation antipsychotic; serotonin dopamine hypothesis

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 CHLORO N [4 METHOXY 3 (1 PIPERAZINYL)PHENYL] 3 METHYL 2 BENZOTHIOPHENESULFONAMIDE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIPAMPERONE; QUETIAPINE; QUINPIROLE; RACLOPRIDE; RISPERIDONE; SB 399885; SEROTONIN; SEROTONIN 6 ANTAGONIST; SERTINDOLE; SPIPERONE; SULPIRIDE; TANDOSPIRONE; THIORIDAZINE; UNCLASSIFIED DRUG; VOLINANSERIN; ZIPRASIDONE; ZOTEPINE;

ACUTE DRUG ADMINISTRATION; CATALEPSY; CHRONIC DRUG ADMINISTRATION; COGNITION; DOPAMINE RELEASE; DOPAMINERGIC ACTIVITY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; NEUROPHARMACOLOGY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; RECEPTOR UPREGULATION; REVIEW; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; TREATMENT RESPONSE;

ANIMALS; ANTIPSYCHOTIC AGENTS; DOPAMINE; DOPAMINE ANTAGONISTS; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PROTEIN ISOFORMS; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SCHIZOPHRENIA; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 50349086333     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00910-2     Document Type: Review

References (85)

1. Andersson J.L., Nomikos G.G., Marcus M., Hertel P., Mathé J.M., and Svensson T.H. Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic systems. Naunyn Schmiedeberg's Arch. Pharmacol. 352 (1995) 374-385
2. 1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience 40 (1991) 399-412
3. Bortolozzi A., Díaz-Mataix L., Toth M., Celada P., and Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology 191 (2007) 745-758
4. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., and Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14 (1996) 87-96
5. Chakos M., Lieberman J., Hoffman E., Bradford D., and Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry 158 (2001) 518-526
6. 1A receptors by clozapine in the primate brain: a PET study. Psychopharmacology 166 (2003) 234-240
7. Davis J.M., Chen N., and Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 60 (2003) 553-564
8. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J. Neurosci. 25 (2005) 10831-10843
9. 125I]SB-258585. Synapse 45 (2002) 191-199
10. Farde L., and Nordström A.-L. PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br. J. Psychiatry 160 Suppl. 17 (1992) 30-33
11. 6 receptor mRNA levels in rat brain. Schizophr. Res. 38 (1999) 7-12
12. Geddes J., and Harrison P. Atypical antipsychotics in the treatment of schizophrenia: systemic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
13. 2A receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur. Neuropsychopharmacol. 11 (2001) 105-110
14. 2A receptor activation enhances dialysis levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats. Neuropharmacology 38 (1999) 315-317
15. 2/3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology 31 (2006) 1027-1035
16. Harvey P.D., and Keefe R.S.E. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. Am. J. Psychiatry 158 (2001) 176-184
17. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907 (2001) 151-155
18. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76 (2001) 1521-1531
19. 1A receptor agonism. Brain Res. 956 (2002) 349-357
20. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 483 (2004) 45-53
21. Kane J., Hönigfeld G., Singer J., Meltzer H.Y., and The Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. Arch. Gen. Psychiatry 45 (1988) 789-796
22. 2 affinity results in the loss of clozapine's atypical antipsychotic action. Neuroreport 13 (2002) 831-835
23. Kapur S., and Remington G. Serotonin-dopamine interaction and its relevance to schizophrenia. Am. J. Psychiatry 153 (1996) 466-476
24. 2 receptors. Implications for atypical antipsychotic action. J. Psychiatry Neurosci. 25 (2000) 161-166
25. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am. J. Psychiatry 158 (2001) 360-369
26. 2 receptor occupancy. Arch. Gen. Psychiatry 57 (2000) 553-559
27. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am. J. Psychiatry 156 (1999) 286-293
28. 2 receptors by clozapine and quetiapine. Neuropsychopharmacology 31 (2006) 1991-2001
29. 2 receptor occupancy levels. Psychiatric Res. 75 (1997) 91-101
30. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288 (1999) 774-781
31. 2A/2C receptor agonist, potentiates amphetamine-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Brain Res. 972 (2003) 216-221
32. Kuroki T., Nakahara T., Nagao N., Motomura K., Hashimoto K., and Kanba S. Dual effects of aripiprazole on prefrontal dopamine release. Bull. Jpn Soc. Neurochem. 46 (2007) 493
33. Leucht S., Pitschel-Walz G., Engel R.R., and Kissling W. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials. Am. J. Psychiatry 159 (2002) 180-190
34. Leucht S., Wahlbeck K., Hamann J., and Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 361 (2003) 1581-1589
35. 2 receptors. Psychopharmacology 112 (1993) S40-S54
36. 6 receptor antagonist SB-399885 potentiates haloperidol and risperidone-induced dopamine efflux in the medial prefrontal cortex or hippocampus. Brain Res. 1134 (2007) 70-78
37. Li Z., Ichikawa J., Dai J., and Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. Eur. J. Pharmacol. 493 (2004) 75-83
38. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947 (2002) 157-165
39. Lohr J.B., and Braff D.L. The value of referring to recently introduced antipsychotics as "second generation". Am. J. Psychiatry 160 (2003) 1371-1372
40. 1A receptor occupancy in patients with schizophrenia: a triple trace PET study. Am. J. Psychiatry 164 (2007) 1411-1417
41. 2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am. J. Psychiatry 161 (2004) 818-825
42. 2 receptor density in rat cerebral cortex. Life Sci. 45 (1989) 1397-1406
43. McEvoy J.P., Lieberman J.A., Stroup T.S., Davis S.M., Meltzer H.Y., Rosenheck R.A., Swartz M.S., Perkins D.O., Keefe R.S., Davis C.E., Severe J., Hsiao J.K., and CATIE Investigators. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am. J. Psychiatry 163 (2006) 600-610
44. Meltzer H.Y. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99 (1989) S18-S27
45. Meltzer H.Y., Li Z., Kaneda Y., and Ichikawa J. Serotonin receptors: their key role in drugs to schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 1159-1172
46. i values. J. Pharmacol. Exp. Ther. 251 (1989) 238-246
47. Meltzer H.Y., and McGurk S.R. The effects of clozapine, risperidone and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25 (1999) 233-256
48. 1A receptors. J. Pharmacol. Exp. Ther. 295 (2000) 853-861
49. 2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37 (1998) 953-955
50. 6 receptor antagonist SB-271046 on the activity of midbrain dopamine neurons in rats: an in vivo electrophysiological study. Synapse 52 (2004) 20-28
51. Moghaddam B., and Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54 (1990) 1755-1760
52. Moncrieff J. Clozapine vs. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br. J. Psychiatry 183 (2003) 161-166
53. 18F-fallypride. Neuropsychopharmacology 25 (2001) 476-488
54. 35S]GTPγS binding study. Eur. J. Pharmacol. 355 (1998) 245-256
55. 2C receptor mutant mice. Diabetes 52 (2003) 315-320
56. 2A receptor occupancy in schizophrenic patients. Am. J. Psychiatry 156 (1999) 869-875
57. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., and Kerwin R.W. Limbic selectivity of clozapine. Lancet 350 (1997) 490-491
58. 2C receptor gene polymorphism. Lancet 359 (2002) 2086-2087
59. 1A receptor activation contributes to ziprasidone-induced dopamine release in the rat prefrontal cortex. Biol. Psychiatry 48 (2000) 229-237
60. 1C receptors. J. Pharmacol. Exp. Ther. 260 (1992) 1361-1365
61. Roth B.L., Craigo S.E., Choudhary M.S., Uluer A., Monsma Jr. F.J., Shen Y., Meltzer H.Y., and Sibley D.R. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J. Pharmcol. Exp. Ther. 268 (1994) 1403-1410
62. Roth B.L., Scheffler D.J., and Kroeze W.K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat. Rev. Drug Discov. 3 (2004) 353-359
63. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., Gompel P.V., Lesage A.S., De Loore K., and Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 124 (1996) 57-73
64. Seeman P. Dopamine receptors: clinical correlates. In: Bloom F.E., and Kupfer D.J. (Eds). Psychopharmacology: The Fourth Generation of Progress (1995), Raven Press, New York 295-302
65. Seeman P. Atypical antipsychotics: mechanism of action. Can. J. Psychiatry 47 (2002) 27-38
66. Seeman P., and Tallerico T. Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. Am. J. Psychiatry 156 (1999) 876-884
67. Semba J., Watanabe A., Kito S., and Toru M. Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain. Neuropharmacology 34 (1995) 785-791
68. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., Roth B.L., and Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
69. 3 as a target for neuroleptics. Nature 347 (1990) 146-151
70. 2 receptor occupancy. Psychopharmacology 160 (2002) 107-112
71. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., and Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 158 (2001) 1722-1725
72. 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95 (2007) 158-168
73. 11C]FLB457. Am. J. Psychiatry 158 (2001) 926-930
74. 123I-5-I-R-91150. Br. J. Psychiatry 173 (1998) 236-241
75. 2A receptors: a PET study of chlorpromazine, clozapine and amisulpride in schizophrenic patients. Am. J. Psychiatry 155 (1998) 505-508
76. Volonté M., Monferini E., Cerutti M., Fodritto F., and Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69 (1997) 182-190
77. Wadenberg M.L., and Ahlenius S. Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: enhancement of antipsychotic-like effects without catalepsy. J. Neural. Transm. Gen. Sect. 83 (1991) 43-53
78. Westerink B.H.C., Kawahara Y., De Boer P., Geels C., De Vries J.B., Wikstrom H.V., Van Kalkeren A., Van Vliet B., Kruse C.G., and Long S.K. Antipsychotic drugs classified by their effects on the release of dopamine and noradrenaline in the prefrontal cortex and striatum. Eur. J. Pharmacol. 412 (2001) 127-138
79. Woodward N.D., Purdon S.E., Meltzer H.Y., and Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int. J. Neuropsychopharmacol. 8 (2005) 457-472
80. 2 dopamine receptor blockade with haloperidol or new antipsychotic drugs in patients with schizophrenia. Br. J. Psychiatry 179 (2001) 503-508
81. Yamamoto B.K., and Cooperman M.A. Differential effects of chronic antipsychotic drug treatment on extracellular glutamate and dopamine concentrations. J. Neurosci. 14 (1994) 4159-4166
82. 11C]raclopride. Neuropsychopharmacology 27 (2002) 248-259
83. Youngren K.D., Inglis F.M., Pivirotto P.J., Jedema H.P., Bradberry C.W., Goldman-Rakic P.S., Roth R.H., and Moghaddam B. Clozapine preferentially increases dopamine release in the rhesus monkey prefrontal cortex compared with the caudate nucleus. Neuropsychopharmacology 20 (1999) 403-412
84. Youngren K.D., Moghaddam B., Bunney B.S., and Roth R.H. Preferential activation of dopamine overflow in prefrontal cortex produced by chronic clozapine treatment. Neurosci. Lett. 165 (1994) 41-44
85. Yu Y., Tsai S.-J., Lin C.-H., Hsu C.-P., Yang K.-H., and Hong C.-J. Serotonin-6 receptor variant (C267T) and clinical response to clozapine. Neuroreport 10 (1999) 1231-1233